Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 85

1.

Inactive USP14 and inactive UCHL5 cause accumulation of distinct ubiquitinated proteins in mammalian cells.

Chadchankar J, Korboukh V, Conway LC, Wobst HJ, Walker CA, Doig P, Jacobsen SJ, Brandon NJ, Moss SJ, Wang Q.

PLoS One. 2019 Nov 8;14(11):e0225145. doi: 10.1371/journal.pone.0225145. eCollection 2019.

2.

Phosphorylation of Glutamine Synthetase on Threonine 301 Contributes to Its Inactivation During Epilepsy.

Huyghe D, Denninger AR, Voss CM, Frank P, Gao N, Brandon N, Waagepetersen HS, Ferguson AD, Pangalos M, Doig P, Moss SJ.

Front Mol Neurosci. 2019 May 21;12:120. doi: 10.3389/fnmol.2019.00120. eCollection 2019.

3.

Mouse Red Blood Cell-Mediated Rare Xenobiotic Phosphorylation of a Drug Molecule Not Intended to Be a Kinase Substrate.

Gu C, Wen S, Doig P, Gangl E, Zheng X, Wang Y, Johannes JW.

Drug Metab Dispos. 2017 Dec;45(12):1345-1353. doi: 10.1124/dmd.117.076869. Epub 2017 Oct 6.

PMID:
28986473
4.

Resistance mutations generate divergent antibiotic susceptibility profiles against translation inhibitors.

Cocozaki AI, Altman RB, Huang J, Buurman ET, Kazmirski SL, Doig P, Prince DB, Blanchard SC, Cate JH, Ferguson AD.

Proc Natl Acad Sci U S A. 2016 Jul 19;113(29):8188-93. doi: 10.1073/pnas.1605127113. Epub 2016 Jul 5.

5.

Corrigendum: Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases.

Basarab GS, Kern GH, McNulty J, Mueller JP, Lawrence K, Vishwanathan K, Alm RA, Barvian K, Doig P, Galullo V, Gardner H, Gowravaram M, Huband M, Kimzey A, Morningstar M, Kutschke A, Lahiri SD, Perros M, Singh R, Schuck VJ, Tommasi R, Walkup G, Newman JV.

Sci Rep. 2015 Sep 18;5:14157. doi: 10.1038/srep14157. No abstract available.

6.

Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases.

Basarab GS, Kern GH, McNulty J, Mueller JP, Lawrence K, Vishwanathan K, Alm RA, Barvian K, Doig P, Galullo V, Gardner H, Gowravaram M, Huband M, Kimzey A, Morningstar M, Kutschke A, Lahiri SD, Perros M, Singh R, Schuck VJ, Tommasi R, Walkup G, Newman JV.

Sci Rep. 2015 Jul 14;5:11827. doi: 10.1038/srep11827. Erratum in: Sci Rep. 2015;5:14157.

7.

Discovery of Novel DNA Gyrase Inhibiting Spiropyrimidinetriones: Benzisoxazole Fusion with N-Linked Oxazolidinone Substituents Leading to a Clinical Candidate (ETX0914).

Basarab GS, Doig P, Galullo V, Kern G, Kimzey A, Kutschke A, Newman JP, Morningstar M, Mueller J, Otterson L, Vishwanathan K, Zhou F, Gowravaram M.

J Med Chem. 2015 Aug 13;58(15):6264-82. doi: 10.1021/acs.jmedchem.5b00863. Epub 2015 Jul 24.

PMID:
26158756
8.

Inhibition of Neisseria gonorrhoeae Type II Topoisomerases by the Novel Spiropyrimidinetrione AZD0914.

Kern G, Palmer T, Ehmann DE, Shapiro AB, Andrews B, Basarab GS, Doig P, Fan J, Gao N, Mills SD, Mueller J, Sriram S, Thresher J, Walkup GK.

J Biol Chem. 2015 Aug 21;290(34):20984-94. doi: 10.1074/jbc.M115.663534. Epub 2015 Jul 6.

9.

Novel DNA gyrase inhibiting spiropyrimidinetriones with a benzisoxazole scaffold: SAR and in vivo characterization.

Basarab GS, Brassil P, Doig P, Galullo V, Haimes HB, Kern G, Kutschke A, McNulty J, Schuck VJ, Stone G, Gowravaram M.

J Med Chem. 2014 Nov 13;57(21):9078-95. doi: 10.1021/jm501174m. Epub 2014 Oct 17.

PMID:
25286019
10.

Rational design of inhibitors of the bacterial cell wall synthetic enzyme GlmU using virtual screening and lead-hopping.

Doig P, Boriack-Sjodin PA, Dumas J, Hu J, Itoh K, Johnson K, Kazmirski S, Kinoshita T, Kuroda S, Sato TO, Sugimoto K, Tohyama K, Aoi H, Wakamatsu K, Wang H.

Bioorg Med Chem. 2014 Nov 1;22(21):6256-69. doi: 10.1016/j.bmc.2014.08.017. Epub 2014 Sep 16.

PMID:
25262942
11.

Overexpression of Pseudomonas aeruginosa LpxC with its inhibitors in an acrB-deficient Escherichia coli strain.

Gao N, McLeod SM, Hajec L, Olivier NB, Lahiri SD, Bryan Prince D, Thresher J, Ross PL, Whiteaker JD, Doig P, Li AH, Hill PJ, Cornebise M, Reck F, Hale MR.

Protein Expr Purif. 2014 Dec;104:57-64. doi: 10.1016/j.pep.2014.09.006. Epub 2014 Sep 18.

PMID:
25240855
12.

Response from Dr. Peter Doig.

Doig P.

J Can Dent Assoc. 2013;79:d125. No abstract available.

PMID:
24059483
13.

CDA advocacy: making a difference in oral health care.

Doig P.

J Can Dent Assoc. 2013;79:d119. No abstract available.

14.

Screening-based discovery of the first novel ATP competitive inhibitors of the Staphylococcus aureus essential enzyme UMP kinase.

Doig P, Gorseth E, Nash T, Patten A, Gao N, Blackett C.

Biochem Biophys Res Commun. 2013 Jul 19;437(1):162-7. doi: 10.1016/j.bbrc.2013.06.060. Epub 2013 Jun 24.

PMID:
23806686
15.

Developing a national oral health strategy.

Doig P.

J Can Dent Assoc. 2013;79:d85. No abstract available.

16.

In vivo validation of thymidylate kinase (TMK) with a rationally designed, selective antibacterial compound.

Keating TA, Newman JV, Olivier NB, Otterson LG, Andrews B, Boriack-Sjodin PA, Breen JN, Doig P, Dumas J, Gangl E, Green OM, Guler SY, Hentemann MF, Joseph-McCarthy D, Kawatkar S, Kutschke A, Loch JT, McKenzie AR, Pradeepan S, Prasad S, Martínez-Botella G.

ACS Chem Biol. 2012 Nov 16;7(11):1866-72. doi: 10.1021/cb300316n. Epub 2012 Aug 28.

PMID:
22908966
17.

An aminoquinazoline inhibitor of the essential bacterial cell wall synthetic enzyme GlmU has a unique non-protein-kinase-like binding mode.

Larsen NA, Nash TJ, Morningstar M, Shapiro AB, Joubran C, Blackett CJ, Patten AD, Boriack-Sjodin PA, Doig P.

Biochem J. 2012 Sep 15;446(3):405-13. doi: 10.1042/BJ20120596.

PMID:
22721802
18.

Bacterial DNA replication enzymes as targets for antibacterial drug discovery.

Sanyal G, Doig P.

Expert Opin Drug Discov. 2012 Apr;7(4):327-39. doi: 10.1517/17460441.2012.660478. Epub 2012 Feb 21. Review.

PMID:
22458504
19.

Surveillance of equine respiratory viruses in Ontario.

Diaz-Mendez A, Viel L, Hewson J, Doig P, Carman S, Chambers T, Tiwari A, Dewey C.

Can J Vet Res. 2010 Oct;74(4):271-8.

20.

Exploring 8-benzyl pteridine-6,7-diones as inhibitors of glutamate racemase (MurI) in gram-positive bacteria.

Breault GA, Comita-Prevoir J, Eyermann CJ, Geng B, Petrichko R, Doig P, Gorseth E, Noonan B.

Bioorg Med Chem Lett. 2008 Dec 1;18(23):6100-3. doi: 10.1016/j.bmcl.2008.10.022. Epub 2008 Oct 8.

PMID:
18947997
21.

Exploring 9-benzyl purines as inhibitors of glutamate racemase (MurI) in Gram-positive bacteria.

Geng B, Breault G, Comita-Prevoir J, Petrichko R, Eyermann C, Lundqvist T, Doig P, Gorseth E, Noonan B.

Bioorg Med Chem Lett. 2008 Aug 1;18(15):4368-72. doi: 10.1016/j.bmcl.2008.06.068. Epub 2008 Jun 24.

PMID:
18614367
22.

Treatment of log yard runoff using a r-circulating sand filtration process.

Doig P, Van Poppelen P, Baldwin SA.

Environ Technol. 2007 Jul;28(7):807-17.

PMID:
17674655
23.

Prohibition of clenbuterol use in food-producing animals.

Doig PA.

Can Vet J. 1998 Jun;39(6):334. No abstract available.

25.

Audit of emergency medical admissions during the winter 1997/1998.

Grant K, Doig P, Honeyman L.

Health Bull (Edinb). 2000 May;58(3):210-4.

PMID:
12813827
26.

Identification of a mutant bovine herpesvirus-1 (BHV-1) in post-arrival outbreaks of IBR in feedlot calves and protection with conventional vaccination.

van Drunen Littel-van den Hurk S, Myers D, Doig PA, Karvonen B, Habermehl M, Babiuk LA, Jelinski M, Van Donkersgoed J, Schlesinger K, Rinehart C.

Can J Vet Res. 2001 Apr;65(2):81-8.

27.
28.

Comparative genomics of Helicobacter pylori: analysis of the outer membrane protein families.

Alm RA, Bina J, Andrews BM, Doig P, Hancock RE, Trust TJ.

Infect Immun. 2000 Jul;68(7):4155-68.

29.

Clinical efficacy and tolerance of meloxicam in dogs with chronic osteoarthritis.

Doig PA, Purbrick KA, Hare JE, McKeown DB.

Can Vet J. 2000 Apr;41(4):296-300.

30.

Dimethyl sulfoxide and alcohol--a potentially dangerous combination.

Doig PA.

Can Vet J. 1999 Nov;40(11):755-6. No abstract available.

31.

Helicobacter pylori physiology predicted from genomic comparison of two strains.

Doig P, de Jonge BL, Alm RA, Brown ED, Uria-Nickelsen M, Noonan B, Mills SD, Tummino P, Carmel G, Guild BC, Moir DT, Vovis GF, Trust TJ.

Microbiol Mol Biol Rev. 1999 Sep;63(3):675-707. Review.

32.

Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori.

Alm RA, Ling LS, Moir DT, King BL, Brown ED, Doig PC, Smith DR, Noonan B, Guild BC, deJonge BL, Carmel G, Tummino PJ, Caruso A, Uria-Nickelsen M, Mills DM, Ives C, Gibson R, Merberg D, Mills SD, Jiang Q, Taylor DE, Vovis GF, Trust TJ.

Nature. 1999 Jan 14;397(6715):176-80. Erratum in: Nature 1999 Feb 25;397(6721):719.

PMID:
9923682
33.

Veterinary medicine in Canada: opportunity for renewal.

Guernsey G, Doig P, Fretz P, McKelvey D.

Can Vet J. 1998 Jul;39(7):407-9. No abstract available.

34.

[Veterinary medicine in Canada: a time for renewal].

Guernsey G, Doig P, Fretz P, McKelvey D.

Can Vet J. 1998 Aug;39(8):467-9. French. No abstract available.

35.

Molecular Characterization of H. pylori Surface Antigens.

Doig P, O'Toole PW, Trust TJ.

Methods Mol Med. 1997;8:177-89. doi: 10.1385/0-89603-381-3:177.

PMID:
21351033
36.
37.

Identification and characterization of genes required for post-translational modification of Campylobacter coli VC167 flagellin.

Guerry P, Doig P, Alm RA, Burr DH, Kinsella N, Trust TJ.

Mol Microbiol. 1996 Jan;19(2):369-78.

PMID:
8825781
38.

The putative neuraminyllactose-binding hemagglutinin HpaA of Helicobacter pylori CCUG 17874 is a lipoprotein.

O'Toole PW, Janzon L, Doig P, Huang J, Kostrzynska M, Trust TJ.

J Bacteriol. 1995 Nov;177(21):6049-57.

39.

Isolation and characterization of a conserved porin protein from Helicobacter pylori.

Doig P, Exner MM, Hancock RE, Trust TJ.

J Bacteriol. 1995 Oct;177(19):5447-52.

40.

Stimulation of interleukin-8 production in epithelial cell lines by Helicobacter pylori.

Huang J, O'Toole PW, Doig P, Trust TJ.

Infect Immun. 1995 May;63(5):1732-8.

41.

Isolation and characterization of a family of porin proteins from Helicobacter pylori.

Exner MM, Doig P, Trust TJ, Hancock RE.

Infect Immun. 1995 Apr;63(4):1567-72.

42.
43.
44.

Partial characterization of a Candida albicans fimbrial adhesin.

Yu L, Lee KK, Ens K, Doig PC, Carpenter MR, Staddon W, Hodges RS, Paranchych W, Irvin RT.

Infect Immun. 1994 Jul;62(7):2834-42.

46.
47.

Thin, aggregative fimbriae mediate binding of Salmonella enteritidis to fibronectin.

Collinson SK, Doig PC, Doran JL, Clouthier S, Trust TJ, Kay WW.

J Bacteriol. 1993 Jan;175(1):12-8.

48.

Structural comparison of urease and a GroEL analog from Helicobacter pylori.

Austin JW, Doig P, Stewart M, Trust TJ.

J Bacteriol. 1992 Nov;174(22):7470-3.

49.

Production of a conserved adhesin by the human gastroduodenal pathogen Helicobacter pylori.

Doig P, Austin JW, Kostrzynska M, Trust TJ.

J Bacteriol. 1992 Apr;174(8):2539-47.

50.

Binding of nonmucoid Pseudomonas aeruginosa to normal human intestinal mucin and respiratory mucin from patients with cystic fibrosis.

Sajjan U, Reisman J, Doig P, Irvin RT, Forstner G, Forstner J.

J Clin Invest. 1992 Feb;89(2):657-65.

Supplemental Content

Support Center